Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?
- PMID: 37406224
- DOI: 10.1093/bjd/ljad224
Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?
Conflict of interest statement
Conflicts of interest: C.A.M. declares no conflicts of interest. J.R.I. receives a stipend as Editor-in-Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate. He is a consultant for AbbVie, Boehringer Ingelheim, ChemoCentryx, Citryll, Novartis, UCB Pharma and UNION Therapeutics, and has served on advisory boards for Insmed, Kymera Therapeutics and Viela Bio. He is co-copyright holder of HiSQOL, Investigator Global Assessment and Patient Global Assessment instruments for hidradenitis suppurativa. His department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. A.V.M. reports consultancy/advisory board disease-relevant honoraria from AbbVie, Boehringer Ingelheim, Novartis, Pfizer, Sanofi and UCB.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
